| Trial ID: | L5692 |
| Source ID: | NCT01240252
|
| Associated Drug: |
Human Insulin
|
| Title: |
Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Human insulin
|
| Outcome Measures: |
Primary: Proportion of insulin resistant patients with elevated serine/threonine phosphorylation of IRS-1 in muscle., IRS-1 will be immunoprecipitated from percutaneous muscle biopsies, resolved by gel electrophoresis, digested with trypsin, and analyzed by high-performance liquid chromatography nanospray tandem mass spectrometry (MS/MS) analysis, one month from date of volunteer study | Secondary: Quantitative assay of the ability of insulin to clear glucose from the blood in insulin resistant patients., The glucose clamp gives a quantitative measure, in mass per unit body weight per minute, of the ability of insulin to cause glucose to disappear from the blood, one month from date if volunteer study
|
| Sponsor/Collaborators: |
Sponsor: Mayo Clinic | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
14
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2012-03
|
| Completion Date: |
2012-07
|
| Results First Posted: |
|
| Last Update Posted: |
2013-06-05
|
| Locations: |
Mayo Clinic in Arizona, Scottsdale, Arizona, 85259, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01240252
|
